Pharmacist Diabetes Podcast 45 credit minutes

GLP-1 receptor agonists remain an important and rapidly changing area of pharmacy practice, with new therapies, expanding indications, and evolving safety considerations shaping patient care. This course reviews recent developments in GLP-1 therapy, including newly approved medications, emerging evidence related to nutrition and oral health, and practical considerations for patient counseling and long-term management. You will be better prepared to evaluate new evidence, counsel patients on the safe and effective use of GLP-1 therapies, and incorporate recent updates into clinical practice. 

Available in Subscription

This course is included in the following subscription:

Pharmacist CE Subscription

Pharmacist CE Subscription

Renewed Annually
$99.00 / year

Learning Objectives

1. Describe recent developments in GLP-1 therapies, including newly approved medications.
2. Explain pharmacist-relevant considerations for counseling, safety monitoring, and long-term management of patients receiving GLP-1 therapies. 

Faculty

Rachel Maynard, PharmD

Disclosures:

Rachel Maynard has no relevant financial relationships with ineligible companies to disclose.

Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP

Disclosures:

Jennifer Goldman is a member of the speakers bureau for Novo Nordisk, Amgen, Lilly, Xeris, CeQur, and Abbott Diabetes. All relevant financial relationships have been mitigated.

Course Details